{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"14"},{"groupId":"OG008","value":"5"}],"units":"Participants"}],"description":"Number and percentage of participants experiencing dose-limiting toxicities (DLT) collected from start of enrollment through the first 28 days of Cycle 1 as assessed by CTCAE v5.0 (Part 1).","groups":[{"description":"Participants received 1.8 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG000","title":"Dose 1"},{"description":"Participants received 3.6 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG001","title":"Dose 2"},{"description":"Participants received 7.2 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG002","title":"Dose 3"},{"description":"Participants received 12 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG003","title":"Dose 4"},{"description":"Participants received 18 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG004","title":"Dose 5"},{"description":"Participants received 27 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG005","title":"Dose 6"},{"description":"Participants received 40 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG006","title":"Dose 7"},{"description":"Participants received 60 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG007","title":"Dose 8"},{"description":"Participants received 80 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"OG008","title":"Dose 9"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The DLT Evaluable Population consists of all participants who either met the following minimal exposure criteria and have sufficient safety evaluations without having a DLT, or have experienced a DLT during the DLT assessment period. Participants who did not experience a DLT in Dose Escalation must have received all of their scheduled doses (Days 1, 8, and 15) during the DLT assessment period with completed follow-up data available through 28 days of Cycle 1 to be DLT-assessable.","reportingStatus":"POSTED","timeFrame":"28 days","title":"Number and Percentage of Participants Experiencing Dose-limiting Toxicities","type":"PRIMARY","unitOfMeasure":"Participants"}